Lapses in Adverse Event Reporting Bring Warning Letter for Navinta

Drug Industry Daily
A A
Navinta has received a warning letter from the FDA for violating requirements for postmarketing adverse drug experience (PADE) reporting.

To View This Article:

Login

Subscribe To Drug Industry Daily